Cargando…
Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin
A central treatment resistance mechanism in solid tumors is the maintenance of epithelial junctions between malignant cells that prevent drug penetration into the tumor. We have developed a small recombinant protein (JO-1) that triggers the transient opening of intercellular junctions and thus incre...
Autores principales: | Richter, Maximilian, Yumul, Roma, Wang, Hongjie, Saydaminova, Kamola, Ho, Martin, May, Drew, Baldessari, Audrey, Gough, Michael, Drescher, Charles, Urban, Nicole, Roffler, Steve, Zubieta, Chloé, Carter, Darrick, Fender, Pascal, Lieber, André |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445001/ https://www.ncbi.nlm.nih.gov/pubmed/26029716 http://dx.doi.org/10.1038/mtm.2015.5 |
Ejemplares similares
-
Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic
por: Richter, Maximilian, et al.
Publicado: (2016) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009) -
Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019) -
Translational development of a tumor junction opening technology
por: Kim, Jiho, et al.
Publicado: (2022)